Human papillomavirus genotype distribution in head and neck cancer: Informing developing strategies for cancer prevention, diagnosis, treatment and surveillance

Mashiana, S.S.; Navale, Pooja; Khandakar, Binny; Sobotka, Stanislaw; Posner, Marshal R.; Miles, Brett A.; Zhang, W.; Gitman, Melissa R.; Bakst, Richard L.; Genden, Eric M.; Westra, William H.

doi:10.1016/j.oraloncology.2020.105109

Cited by 20 publications

(23 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HPV 44 belongs to a mucosotropic group of HPVs found in benign and malignant lesions of the anogenital tract and fortuitously in tissues and lesions of the oral cavity, oropharynx, and esophagus [ 27 ]. A number of samples in our study contained more than one HPV type, which is in line with some [ 32 , 35 , 42 , 43 , 44 , 57 , 65 ] but not all studies [ 33 ].…”

Section: Discussionsupporting

confidence: 88%

“…Our results support the epidemiological evidence that some head and neck cancers are caused by HPV and that the main risk factors of HNSCC are tobacco and alcohol abuse [1]. The overall prevalence of HPV in the HNSCC group was 42.1%, which is in line with a large number of reports of HPV DNA (2.4-74%) in head and neck cancer patients [8,[31][32][33]40,[50][51][52][53][54][55][56][57][58][59]. The data concerning HPV infection in HNSCC patients in Poland are very inconclusive.…”

Section: Hpv Infection In Hnsccsupporting

confidence: 90%

“…Detection of HPV is performed using different methods, including signal amplification assays, assays based on hybridization, real-time PCR, microarrays, and next-generation sequencing [ 29 , 30 ]. The methodology used in our study detects 33 subtypes, including the non-oncogenic HPV 43/44, while other assays detect only oncogenic genotypes and fewer non-oncogenic genotypes, without HPV 43/44 [ 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 ]. Some researchers have used tests to detect all known high-risk and low-risk genotypes.…”

Section: Discussionmentioning

confidence: 99%

“…Incidence rates for oral and oropharyngeal cancer related to HPV infections are on the increase in some countries, especially among men [9][10][11], but the global prevalence and the genotype of HPV infection in head and neck squamous cell carcinoma (HNSCC) remain obscure [8,9]. About 200 types of HPV have been identified and classified into two major groups (i.e., high-risk and low-risk subtypes), depending on their ability to trigger neoplastic transformation [1,3], 25 types of which (1,2,3,4,6,7,10,11,13,16,18,31,32,33,35,40,45,52,55,57,58,59,69,72,73) are associated with oral lesions [12].…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The Prevalence of High- and Low-Risk Types of HPV in Patients with Squamous Cell Carcinoma of the Head and Neck, Patients with Chronic Tonsillitis, and Healthy Individuals Living in Poland

et al. 2021

View full text Add to dashboard Cite

Human papillomavirus (HPV) is a virus with the potential to infect human epithelial cells and an etiological agent of many types of cancer, including head and neck cancer. The aim of the study was to determine the prevalence of HPV infection in patients with head and neck squamous cell carcinoma (HNSCC), patients with chronic tonsillitis, and healthy individuals, and to establish high- and low-risk HPV genotypes in these groups. The objectives also comprised the delineation of the relationship between the infection with high- or low-risk HPV subtypes and clinicopathological and demographic characteristics of the study groups. This study was composed of 76 patients diagnosed with HNSCC, 71 patients with chronic tonsillitis, and 168 cases without either of these conditions (the control group). HPV detection and identification of subtypes were performed on isolated DNA using a test which allowed detection of 33 common high-risk and low-risk HPV subtypes. The prevalence of HPV infection was 42.1%, 25.4%, and 37.5% in HNSCC, chronic tonsillitis, and control groups, respectively. HPV 16 was the most prevalent genotype in all groups and the non-oncogenic HPV 43/44 was frequent in HNSCC patients. This analysis provides insight into the prevalence of oral oncogenic and non-oncogenic HPVs in patients with head and neck cancer, patients with chronic tonsillitis and healthy individuals, and leads to the conclusion that further investigations are warranted to examine a larger cohort of patients focusing on high- and low-risk HPV genotypes. Efforts should be focused on screening and prevention strategies, and therefore, it is important to introduce tools for effective detection of HPV genotypes. Furthermore, given the role of vaccines against oral HPV infection, our observations lead to the suggestion that HPV vaccination should be of considerable importance in public health strategies.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: Hpv Infection In Hnsccsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Prevalence of High- and Low-Risk Types of HPV in Patients with Squamous Cell Carcinoma of the Head and Neck, Patients with Chronic Tonsillitis, and Healthy Individuals Living in Poland

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In parallel, we implemented a bioinformatics-based approach to define local specificity of potential amplicon regions by comparing the HPV16 and HPV18 genomes. We chose these two genomes as they represent the highest and second highest HPV types in HPV+ cancers [ 29 ], respectively. We chose to use an 80 nucleotide sliding window to approximate the size of a small primer-probe amplicon-based assay (2 × 25 nt primers + 30 nt probe), given that most abundant cell free DNA expected to be accessible to standard ddPCR assay-design is in the range of 73–165 nts [ 30 ].…”

Section: Resultsmentioning

confidence: 99%

Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent/metastatic head and neck squamous cell carcinoma

et al. 2021

View full text Add to dashboard Cite

Despite the rising incidence of human papillomavirus related (HPV+) oropharyngeal squamous cell carcinoma (OPSCC), treatment of metastatic disease remains palliative. Even with new treatments such as immunotherapy, response rates are low and can be delayed, while even mild tumor progression in the face of an ineffective therapy can lead to rapid death. Real-time biomarkers of response to therapy could improve outcomes by guiding early change of therapy in the metastatic setting. Herein, we developed and analytically validated a new droplet digital PCR (ddPCR)-based assay for HPV16 circulating tumor DNA (ctDNA) and evaluated plasma HPV16 ctDNA for predicting treatment response in metastatic HPV+ OPSCC. We found that longitudinal changes HPV16 ctDNA correlate with treatment response and that ctDNA responses are observed earlier than conventional imaging (average 70 days, range: 35-166). With additional validation in multi-site studies, this assay may enable early identification of treatment failure, allowing patients to be directed promptly toward clinical trials or alternative therapies.

show abstract

Neoplasms of the Head and Neck

Ferris¹,

Garden²,

Saba³

2022

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview Head and neck cancers (HNCs) comprise a diverse group of malignancies affecting the upper aerodigestive tract. The most common tumor type is squamous cell carcinoma. While the main risk factors for HNC remain tobacco and alcohol abuse, oncogenic viruses such as human papilloma virus and Epstein–Barr virus play a major carcinogenic role in tumors of the oropharynx and nasopharynx respectively. The management of head and neck malignancies is site and histology specific and requires a multidisciplinary team approach. Immunotherapy has become the standard of care in the treatment of advanced metastatic squamous cell cancers. In this article, we will review the current knowledge of HNC, with focus on squamous and salivary cancers, and discuss ongoing and future research aiming to improve the management and outcomes of patients with these malignancies.

show abstract

Human papillomavirus genotype distribution in head and neck cancer: Informing developing strategies for cancer prevention, diagnosis, treatment and surveillance

Cited by 20 publications

References 39 publications

The Prevalence of High- and Low-Risk Types of HPV in Patients with Squamous Cell Carcinoma of the Head and Neck, Patients with Chronic Tonsillitis, and Healthy Individuals Living in Poland

The Prevalence of High- and Low-Risk Types of HPV in Patients with Squamous Cell Carcinoma of the Head and Neck, Patients with Chronic Tonsillitis, and Healthy Individuals Living in Poland

Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent/metastatic head and neck squamous cell carcinoma

Neoplasms of the Head and Neck

Contact Info

Product

Resources

About